WILLIAMS AND JENSEN, PLLC for GENENTECH INC
What was lobbied
4 issue areas, each in the filer's own words, with who lobbied on it and where.
Budget/Appropriations BUD
Policies impacting drug development and public health preparedness. Policies impacting U.S. address to the Covid-19 pandemic, including H.R. 604 Coronavirus Preparedness and Response Supplemental Appropriations Act, Public Law No: 116-123.; H. R . 6201 Families First Coronavirus Response Act, Public Law No: 116-127; and H. R. 748 CARES Act, Public Law No: 116-136.
| Lobbyist | Covered position, as disclosed |
|---|---|
| CHERYL LYNN JAEGER | Shared employee, Ofc of the Speaker & Ofc of VA 07; Sr Policy Adv, Maj Leader, Rep. Cantor; Sr Policy Adv, Republican Whip, Rep. Cantor; Sr Policy Adv, Majority Whip, Rep. Blunt; Prof Staff House Committee on E & C; Sr LA to Rep. Cox |
Taxation/Internal Revenue Code TAX
General tax issues. Implementation of the Tax Cuts and Jobs Act (P.L. 115-97). Orphan Drug Tax Credit issues.
| Lobbyist | Covered position, as disclosed |
|---|---|
| CHRISTOPHER W HATCHER | — |
| KARINA LYNCH | — |
Health Issues HCR
General education about federal policies impact pharmaceutical development, approval, and reimbursement (including Medicare, Medicaid, ACA issues). General education about FDA approval policies; Drug pricing under 340B Program; IPI drug pricing proposal. S. 2543, Prescription Drug Pricing Reduction Act (PDPRA) of 2019 and H.R. 3, Lower Drug Costs Now Act of 2019. Policies impacting U.S. address to the Covid-19 pandemic, including H.R. 604 Coronavirus Preparedness and Response Supplemental Appropriations Act, Public Law No: 116-123.; H. R . 6201 Families First Coronavirus Response Act, Public Law No: 116-127; and H. R. 748 CARES Act, Public Law No: 116-136.
| Lobbyist | Covered position, as disclosed |
|---|---|
| CHERYL LYNN JAEGER | — |
| KARINA LYNCH | — |
| GEORGE OLSEN | — |
| CHRISTOPHER E. WILCOX | Regional Staff Asst & Staff Asst, Sen. Moynihan ;LA, Leg Counsel, LD & Counsel, Rep. Arcuri; LD & Counsel, Rep. Demings |
Medicare/Medicaid MMM
General education about policies impact pharmaceutical development, approval, and reimbursement including Medicare payment policies. Medicare Part D. S. 2543, Prescription Drug Pricing Reduction Act (PDPRA) of 2019 and H.R. 3, Lower Drug Costs Now Act of 2019. Policies impacting U.S. address to the Covid-19 pandemic, including H.R. 604 Coronavirus Preparedness and Response Supplemental Appropriations Act, Public Law No: 116-123.; H. R . 6201 Families First Coronavirus Response Act, Public Law No: 116-127; and H. R. 748 CARES Act, Public Law No: 116-136.
| Lobbyist | Covered position, as disclosed |
|---|---|
| CHERYL LYNN JAEGER | Shared employee, Ofc of the Speaker & Ofc of VA 7; Sr Policy Adv, Majority Leader, Rep Eric Cantor; Sr Policy Adv, Republican Whip, Rep Eric Cantor; Sr Policy Adv, Majority Whip, Rep. Roy Blunt; Prof Staff House Committee on E&C; Sr LA to Rep C Cox |
| KARINA LYNCH | — |
| GEORGE OLSEN | — |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.